Archived Bulletins

July 04, 2018

The Canadian Cancer Trials Group is currently seeking additional members for our Clinical Research Associates Executive Committee (CRAEC).  Please feel free to distribute this call for volunteers within your clinical trials department, and encourage applications from interested and qualified individuals.

Read More

Published: July 04, 2018
Category: News

Since being diagnosed with multiple myeloma in 2002, Aldo has directed his attention to building an effective national platform to address the needs of the Canadian myeloma community.

Aldo founded Myeloma Canada which is the only national non-profit organization uniquely focused on the needs of the Canadian myeloma community. As a patient-driven, grassroots organization, Myeloma Canada’s provides educational resources to patients and advocate for improved access to new therapies and accelerate patient-focused myeloma research.

Read More

Published: July 04, 2018
Category: Publications
Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
 
Read More

June 20, 2018

Published: June 20, 2018
Category: Trials

The Canadian Cancer Trials Group's (CCTG) Supportive Care (former Symptom Control) Committee (SCC) is currently seeking individuals with interest and experience in supportive care trials to join the SCC Executive. In broad terms (adapted from the CCTG's Terms of Reference) the roles of the Disease Site Committee (DSC) Executive members are to:

Read More

Published: June 20, 2018
Category: Group updates
Implementation of the Delegation of Tasks Log (DTL) in RIPPLE

The Delegation of Tasks Log (DTL) has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network (NCTN) trial where CCTG will be using the DTL is the BLC.4 trial. An active DTL has been added as a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other studies that will be using the DTL initially include MAC.24 and REC.4.

Read More

Published: June 20, 2018
Category: News
CCTG staff is raising funds and awareness for the fight against cancer

The CCTG TRIALBLAZERS have been training hard for this year’s Kingston Relay for Life, June 22, 2018 - 6:00 pm - 12:00 am.

Read More

PA.6 Clinical trial: Dr. Jim Biagi and trial participant Kathleen Kennedy

The PRODIGE 24/CCTG PA.6 trial results suggest that this pancreatic cancer treatment regimen should become standard practice world-wide. Patients who receive this treatment after surgery are almost twice as likely to survive.

Read More

Published: June 20, 2018
Category: News

The abstract for the RELEVANCE/LY.16 study was presented at ASCO on June 3rd, 2018. This study compared the effects of lenalidomide plus rituximab (R2) to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma.

Read More